Jones Financial Companies’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Jones Financial Companies’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-99	Closed	–	–	868
2021 Q4	$0	Buy	+99	New	+$615	﹤0.01%	787

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Jones Financial Companies's SRNE Position: Q1 2022 in Review

Jones Financial Companies sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 99 shares.

Jones Financial Companies first reported a position in SRNE in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

Jones Financial Companies reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Jones Financial Companies sold 99 Sorrento Therapeutics, Inc. shares in Q1 2022.
Jones Financial Companies first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 1 quarter.
Jones Financial Companies's Sorrento Therapeutics, Inc. position peaked at $0 in Q4 2021.
235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Jones Financial Companies's 13F filing for Q1 2022, filed 2 May 2022.